Commercialization Momentum Xenocor's leadership changes in 2026 together with FDA clearance indicate a focused push to scale commercialization of the Saberscope. This creates avenues to engage hospital systems and ambulatory surgery centers through a formal sales and distribution strategy and to recruit global partnerships.

Product Advantage Saberscope is a single use, fog free, articulating laparoscope that can reduce sterilization costs, improve OR turnover, and enhance visualization. Position to MIS and perioperative teams on per-case efficiency, infection control, and potential lower total cost of ownership.

Target Market Main customers are hospitals and ambulatory surgery centers performing minimally invasive surgery. Initial US expansion can leverage the headquarters region, followed by international distributor networks as commercialization accelerates post clearance.

Go To Market With new C level leadership and experienced sales talent, Xenocor is likely to pursue distributor partnerships, exclusive territories, and co marketing. Focus BD efforts on building a robust channel, surgeon champions, and bundled offerings with related imaging and disposable components.

Growth Funding The company has secured funding and is generating revenue, signaling capacity to scale. Propose multi year procurement deals, volume pricing, and partnerships with larger medtech players to accelerate market penetration and ensure consistent demand.